Thomas Cars1, Björn Wettermark2, Robert Löfberg3, Irene Eriksson2, Johan Sundström4, Mikael Lördal5. 1. Public Healthcare Services Committee Administration, Stockholm County Council, Stockholm, Sweden Department of Medical Sciences, Uppsala University, Uppsala, Sweden thomas.cars@sll.se. 2. Public Healthcare Services Committee Administration, Stockholm County Council, Stockholm, Sweden Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 3. Department of Medicine, Karolinska Institutet, Stockholm, Sweden IBD unit at Sophiahemmet, Stockholm, Sweden. 4. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 5. Department of Medicine, Karolinska Institutet, Stockholm, Sweden Centre for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND AND AIMS: Crohn's disease [CD] and ulcerative colitis [UC] are chronic diseases associated with a substantial utilisation of healthcare resources. We aimed to estimate the prevalence of inflammatory bowel disease [IBD], CD, and UC and to describe and compare healthcare utilisation and drug treatment in CD and UC patients. METHODS: This was a cross-sectional study of all patients with a recorded IBD diagnosis in Stockholm County, Sweden. Data on outpatient visits, hospitalisations, surgeries, and drug treatment during 2013 were analysed. RESULTS: A total of 13 916 patients with IBD were identified, corresponding to an overall IBD prevalence of 0.65% [CD 0.27%, UC 0.35%, inflammatory bowel disease unclassified 0.04%]; 49% of all IBD patients were treated with IBD-related drugs. Only 3.6% of the patients received high-dose corticosteroids, whereas 32.4% were treated with aminosalicylates [CD 21.2%, UC 41.0%, p < 0.0001]. More CD patients were treated with biologicals compared with UC patients [CD 9.6%, UC 2.9%, p < 0.0001] and surgery was significantly more common among CD patients [CD 3.0%, UC 0.8%, p < 0.0001]. CONCLUSIONS: This study indicates that patients with CD are the group with the highest medical needs. Patients with CD utilised significantly more healthcare resources [including outpatient visits, hospitalisations, and surgeries] than UC patients. Twice as many CD patients received immunomodulators compared with UC patients and CD patients were treated with biologicals three times more often. These results highlight that CD remains a challenge and further efforts are needed to improve care in these patients.
BACKGROUND AND AIMS: Crohn's disease [CD] and ulcerative colitis [UC] are chronic diseases associated with a substantial utilisation of healthcare resources. We aimed to estimate the prevalence of inflammatory bowel disease [IBD], CD, and UC and to describe and compare healthcare utilisation and drug treatment in CD and UC patients. METHODS: This was a cross-sectional study of all patients with a recorded IBD diagnosis in Stockholm County, Sweden. Data on outpatient visits, hospitalisations, surgeries, and drug treatment during 2013 were analysed. RESULTS: A total of 13 916 patients with IBD were identified, corresponding to an overall IBD prevalence of 0.65% [CD 0.27%, UC 0.35%, inflammatory bowel disease unclassified 0.04%]; 49% of all IBD patients were treated with IBD-related drugs. Only 3.6% of the patients received high-dose corticosteroids, whereas 32.4% were treated with aminosalicylates [CD 21.2%, UC 41.0%, p < 0.0001]. More CD patients were treated with biologicals compared with UC patients [CD 9.6%, UC 2.9%, p < 0.0001] and surgery was significantly more common among CD patients [CD 3.0%, UC 0.8%, p < 0.0001]. CONCLUSIONS: This study indicates that patients with CD are the group with the highest medical needs. Patients with CD utilised significantly more healthcare resources [including outpatient visits, hospitalisations, and surgeries] than UC patients. Twice as many CD patients received immunomodulators compared with UC patients and CD patients were treated with biologicals three times more often. These results highlight that CD remains a challenge and further efforts are needed to improve care in these patients.
Authors: A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis Journal: J Crohns Colitis Date: 2010-01-15 Impact factor: 9.071
Authors: Alexander C Ford; Sunanda V Kane; Khurram J Khan; Jean-Paul Achkar; Nicholas J Talley; John K Marshall; Paul Moayyedi Journal: Am J Gastroenterol Date: 2011-03-15 Impact factor: 10.864
Authors: Michael C Sulz; Uwe Siebert; Marjan Arvandi; Raffaella M Gothe; Johannes Wurm; Roland von Känel; Stephan R Vavricka; Christa Meyenberger; Markus Sagmeister Journal: Eur J Gastroenterol Hepatol Date: 2013-07 Impact factor: 2.566
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Irene Eriksson; Thomas Cars; Fredrik Piehl; Rickard E Malmström; Björn Wettermark; Mia von Euler Journal: Eur J Clin Pharmacol Date: 2017-11-11 Impact factor: 2.953
Authors: Bo Freyschuss; Maria K Svensson; Thomas Cars; Lars Lindhagen; Helena Johansson; Andreas Kindmark Journal: J Bone Miner Res Date: 2022-02-06 Impact factor: 6.390
Authors: Kenechukwu Chudy-Onwugaje; Alexander P Mamunes; David A Schwartz; Sara Horst; Raymond K Cross Journal: Inflamm Bowel Dis Date: 2021-02-16 Impact factor: 5.325
Authors: Yazed AlRuthia; Othman Alharbi; Abdulrahman M Aljebreen; Nahla A Azzam; Majid A Almadi; Ohud H Bahari; Khalid A Almalki; Abdulaziz T Atham; Ahmed S Alanazi; Maria Saeed; Baraa HajkhderMullaissa; Mohammad Alsenaidy; Bander Balkhi Journal: Cost Eff Resour Alloc Date: 2019-12-04